Peter Gottlieb MD

Dr. Gottlieb joined the faculty of the Barbara Davis Center in 1994. His laboratory projects are designed to advance basic knowledge of the immune response to autoantigens in type 1 diabetes with the goal of designing immunotherapies for prediabetes and new onset type 1 subjects. Towards this end, Dr. Gottlieb seeks better understanding of the relationship of autoreactive vs. T regulatory cells, innate immunity, and microbiome in human diabetes.  His aims are to better understand the pathogenesis and natural history of type 1 diabetes as well as to design clinical prevention trials based on rigorous immunological readouts of the disease process. He is the PI for the Colorado center of the NIH funded Type 1 Diabetes TrialNet effort. His research provides ‘bench to bedside’ research of the highest caliber. His work has resulted in over 130 peer-reviewed publications.